Were the Royalty Pharma CFO’s share sales made under a Rule 10b5-1 plan?

Yes. The filing states all reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Terrance P. Coyne on August 8, 2025. Such plans schedule trades in advance, reducing the significance of short-term market conditions when the sales occur.

Royalty Pharma (RPRX) CFO sells 34,791 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of a total of 34,791 Class A Ordinary Shares on April 28, 2026. The shares were sold at a weighted average price of $49.7784 per share through entities TPC RP EPA1 LLC and TPC RP 2021, LLC, under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. Following the transactions, TPC RP EPA1 LLC held 40,136 Class A Ordinary Shares, while TPC RP 2021, LLC held none, and the filing also lists additional direct and IRA-related holdings for Coyne and his spouse.

Insights

CFO Terrance Coyne sold 34,791 Royalty Pharma shares via entities under a pre-set 10b5-1 plan.

The filing shows open-market sales of 34,791 Class A Ordinary Shares of Royalty Pharma plc at a weighted average price of $49.7784 per share on April 28, 2026. The sales were executed by entities TPC RP EPA1 LLC and TPC RP 2021, LLC associated with EVP & CFO Terrance P. Coyne.

A key detail is that all reported transactions occurred pursuant to a Rule 10b5-1 trading plan adopted on August 8, 2025, indicating the trades were pre-scheduled rather than opportunistic. After the sales, TPC RP EPA1 LLC is reported holding 40,136 shares, while TPC RP 2021, LLC holds none, alongside other direct and IRA-related holdings. As a result, the activity appears as a routine liquidity event rather than a change in corporate outlook.

Insider Trade Summary 10b5-1

Net Seller: 34,791 shares ($1,731,840)

Net Sell 6 txns

Insider Coyne Terrance P.

Role EVP & CFO

Sold 34,791 shs ($1.73M)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	32,916	$49.7784	$1.64M
Sale	Class A Ordinary Shares	1,875	$49.7784	$93K
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 0 shares (Indirect, By TPC RP 2021, LLC); Class A Ordinary Shares — 1,500 shares (Direct, null)

Footnotes (1)

All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.18 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Total shares sold: 34,791 shares Weighted average sale price: $49.7784 per share First block sold: 1,875 shares +4 more

7 metrics

Total shares sold 34,791 shares Open-market sales on April 28, 2026

Weighted average sale price $49.7784 per share Multiple trades between $49.46 and $50.18

First block sold 1,875 shares Class A Ordinary Shares via TPC RP EPA1 LLC

Second block sold 32,916 shares Class A Ordinary Shares via TPC RP 2021, LLC

TPC RP EPA1 LLC holdings after sale 40,136 shares Class A Ordinary Shares following April 28, 2026 transactions

Direct holdings 1,500 shares Class A Ordinary Shares held directly after reported date

Spouse IRA holdings 24,170 shares Class A Ordinary Shares held via spouse’s IRA

Key Terms

Rule 10b5-1, Class A Ordinary Shares, open-market sale, weighted average price, +1 more

5 terms

Rule 10b5-1 regulatory

"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Class A Ordinary Shares financial

"Class A Ordinary Shares, transaction_date 2026-04-28, transaction_type non-derivative."

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect ownership financial

"ownership_type: indirect, direct_or_indirect: I, nature_of_ownership: By Spouse / By IRA."

Form 4 Insider Transactions: What Each Field Means →

04/30/2026 - 05:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last)

(First)

(Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Ordinary Shares	04/28/2026		S⁽¹⁾		32,916	D	$49.7784⁽²⁾	0	I	By TPC RP 2021, LLC
Class A Ordinary Shares	04/28/2026		S⁽¹⁾		1,875	D	$49.7784⁽²⁾	40,136	I	TPC RP EPA1 LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.46 to $50.18 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,807,277 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Royalty Pharma (RPRX) CFO Terrance Coyne report in this Form 4?

Terrance P. Coyne, EVP & CFO of Royalty Pharma, reported open-market sales totaling 34,791 Class A Ordinary Shares. The trades occurred on April 28, 2026, through entities associated with him, at a weighted average price of about $49.78 per share under a pre-set 10b5-1 plan.

How many Royalty Pharma shares were sold in the latest insider transaction?

The filing shows total insider sales of 34,791 Class A Ordinary Shares. These were split into transactions of 1,875 shares and 32,916 shares, both executed on April 28, 2026, at a weighted average price of $49.7784 per share through two different Coyne-related entities.

At what price did entities linked to Royalty Pharma’s CFO sell shares?

Shares were sold at a weighted average price of $49.7784 per share. The footnotes explain this reflects multiple trades between $49.46 and $50.18, and that detailed breakdowns by price level are available to investors or regulators upon written request to the holder.

What Royalty Pharma holdings remain with entities associated with the CFO after the sale?

Following the reported transactions, TPC RP EPA1 LLC held 40,136 Class A Ordinary Shares. TPC RP 2021, LLC no longer held shares. The filing also lists additional direct holdings of 1,500 shares and several indirect positions via spouse and IRA accounts with specific share balances.

How is the Royalty Pharma CFO’s ownership split between direct and indirect holdings?

The Form 4 shows 1,500 Class A Ordinary Shares held directly and several indirect positions. These include 1,450 shares held by his spouse, 23,270 by his IRA, 24,170 by his spouse’s IRA, and 40,136 by TPC RP EPA1 LLC after the reported open-market sales.